Grifols (GRFS) Enterprise Value (2009 - 2025)
Grifols (GRFS) posted Enterprise Value of -$965.0 million for Q4 2025, up 8.41% quarter-over-quarter from -$1.1 billion in Q4 2024, and up 8.41% year-on-year from -$890.1 million in Q4 2024.
Grifols (GRFS) Enterprise Value (2009 - 2025) Analysis & Trends
Grifols (GRFS) has reported Enterprise Value for 16 consecutive years, with -$965.0 million the latest figure, recorded in Q4 2025.
- Enterprise Value for Q4 2025 came in at -$965.0 million, up 8.41% year-over-year; the trailing twelve-month figure through Dec 2025 was -$965.0 million (up 8.41% YoY), and the FY2025 annual result was -$965.0 million, up 8.41% from the prior year.
- Enterprise Value was -$965.0 million for Q4 2025 at Grifols, up from -$1.1 billion in the prior quarter.
- Over five years, Enterprise Value peaked at -$594.6 million in Q4 2023 and troughed at -$5.4 billion in Q4 2021.
- Average Enterprise Value over 5 years is -$1.7 billion, with a median of -$965.0 million recorded in 2025.
- Year-over-year, Enterprise Value slumped 678.94% in 2021 and surged 88.77% in 2022.
- Over 5 years, Enterprise Value stood at -$5.4 billion in 2021, then soared by 88.77% to -$604.7 million in 2022, then rose by 1.66% to -$594.6 million in 2023, then tumbled by 77.2% to -$1.1 billion in 2024, then advanced by 8.41% to -$965.0 million in 2025.
- Per Business Quant data, the three most recent Enterprise Value figures were -$965.0 million in Q4 2025, -$1.1 billion in Q4 2024, and -$594.6 million in Q4 2023.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Enterprise Value (Qtr) |
|---|---|---|---|---|---|
| 1 | Eli Lilly | 1,066.16 Bn | 1,060.88 Bn | 16.22 Bn | -5.28 Bn |
| 2 | Johnson & Johnson | 611.69 Bn | 589.64 Bn | 15.96 Bn | -22.05 Bn |
| 3 | AbbVie | 444.34 Bn | 434.99 Bn | 10.78 Bn | -9.35 Bn |
| 4 | Astrazeneca | 284.94 Bn | 277.05 Bn | 12.61 Bn | -7.89 Bn |
| 5 | Merck | 224.23 Bn | 218.58 Bn | 12.09 Bn | -5.65 Bn |
| 6 | Amgen | 195.12 Bn | 183.08 Bn | 5.87 Bn | -12.04 Bn |
| 7 | Gilead Sciences | 156.45 Bn | 148.73 Bn | 5.52 Bn | -7.73 Bn |
| 8 | Pfizer | 136.01 Bn | 123.24 Bn | -1.21 Bn | -12.77 Bn |
| 9 | Novartis Ag | 113.45 Bn | 113.67 Bn | - | 315.00 Mn |
| 10 | Grifols | - | - | - | -964.99 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -964.99 Mn |
| Dec 31, 2024 | -1.05 Bn |
| Dec 31, 2023 | -594.61 Mn |
| Dec 31, 2022 | -604.66 Mn |
| Dec 31, 2021 | -3.04 Bn |
| Dec 31, 2020 | 1.23 Bn |
| Sep 30, 2020 | 2.06 Bn |
| Mar 31, 2020 | 1.84 Bn |
| Dec 31, 2019 | -495.07 Mn |
| Sep 30, 2019 | 578.62 Mn |
| Dec 31, 2018 | -665.06 Mn |
| Sep 30, 2018 | 2.73 Mn |
| Jun 30, 2018 | 4.59 Mn |
| Mar 31, 2018 | 584.68 Mn |
| Dec 31, 2017 | -1.05 Bn |
| Jun 30, 2017 | 6.36 Mn |
| Dec 31, 2016 | -962.14 Mn |
| Sep 30, 2016 | 4.51 Mn |
| Jun 30, 2016 | 4.69 Mn |
| Dec 31, 2015 | -1.25 Bn |